Abstract
Metabolic syndrome and obesity are manifested by different phenotypes, which often occur under the influence of an unhealthy lifestyle, insufficient physical activity and irrational nutrition. However, at present, the issue of phenotyping obesity based on metabolic manifestations and adipose tissue ratio has not been sufficiently studied. The aim. To establish patterns of anthropometric changes, characteristics of carbohydrate and lipid metabolism depending on the obesity phenotype. Material and methods. On the basis of the Vinnytsya Regional Clinical Highly Specialized Endocrinological Center, 88 people were examined, (25 men and 63 women). The average age of the examined group was 37.42±11.77 years. All patients collected anamnesis using the diabetes risk assessment scale developed by the Finnish Diabetes Association (The Finnish Diabetes Risk Score, FINDRISK), underwent an objective examination, and laboratory determinations of lipid and carbohydrate metabolism. Based on the received data, a database was created in Excel (Microsoft Office 2007, USA) and in the Statistica 7 software package. Results. All patients were divided into 4 clinical groups, according to 4 obesity phenotypes. It has been proven that even with normal body weight, patients begin to notice metabolic disorders, which may be associated with an increase in waist circumferences and the percentage of visceral fat, while while in obese patients with phenotype III, no changes in carbohydrate and lipid metabolism were recorded. Systolic and diastolic blood pressure levels did not exceed the reference values, which confirms the presence of metabolically healthy obesity. No significant difference was found when comparing characteristics between the groups of obese and non-obese patients (p>0.05). The strength of the correlation between the percentage of visceral fat and indicators of lipid and carbohydrate metabolism was significantly higher compared to body mass index. Conclusion. The degree of obesity does not have a fundamental effect on the severity of carbohydrate and lipid metabolism disorders, and the progression of changes is based on changes in the percentage of visceral fat.
References
Alharbi TA, Ryan J, Freak-Poli R, Gasevic D, Scali J, Ritchie K, et al. The association of weight loss, weight status, and abdominal obesity with all-cause mortality in older adults. Gerontology. 2022;68(12):1366-74. doi: 10.1159/000522040.
Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health. 2016 Oct;70(10):1024-31. doi: 10.1136/jech-2015-206948.
Liu L, Simon B, Shi J, Mallhi AK, Eisen HJ. Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults. World J Diabetes. 2016 Oct 15;7(18):449-61. doi: 10.4239/wjd.v7.i18.449.
World Health Organization. Obesity and Overweight. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed 7th November 2020].
Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, et al. Obesity Algorithm 2021. Available from: https://obesitymedicine.org/wpcontent/uploads/2021/01/2021-Obesity-Algorithm.pdf [Accessed 7th August 2021].
Зінич ОВ, Шупрович АА, Кушнарьова НМ, Прибила ОВ, Ковальчук АВ, Гуріна НМ, та ін. Показники композиції тіла та обміну сечової кислоти як маркери метаболічного фенотипу у чоловіків з нормоурикемією, хворих на цукровий діабет 2 типу. Клінічна ендокринологія та ендокринна хірургія. 2020;4:50-60 (Zinych OV, Shuprovich AA, Kushnaryova NM, Prybyla OV, Kovalchuk AV, Gurina NM, et al. Indicies of body composition and uric acid metabolism as markers of metabolic phenotype in normouricemic type 2 diabetic man. Clinical Endocrinology Endocrine Surgery. 2020;4:50-60. Ukrainian). doi: 10.30978/CEES-2020-4-50.
Ighbariya A, Weiss R. Insulin resistance, prediabetes, metabolic syndrome: what should every pediatrician know? J Clin Res Pediatr Endocrinol. 2017 Dec 30; 9(Suppl 2):49-57. doi: 10.4274/jcrpe.2017.S005.
Dorcely B, Katz K, Jagannathan R, Chiang SS, Oluwadare B, Goldberg IJ, et al. Novel biomarkers for prediabetes, diabetes, and associated complications. Diabetes Metab Syndr Obes. 2017 Aug 14;10:345-61. doi: 10.2147/DMSO.S100074.
Мусієнко ВА, Марущак МІ. Генетичні маркери цукрового діабету 2 типу. Медична та клінічна хімія. 2019;21(4):184-91 (Musiienko VA, Marushchak MI. Genetic markers of type 2 diabetes. Medical and Clinical Chemistry. 2019;21(4):184-91). doi: 10.11603/mcch.2410-681X.2019.v.i4.10688.
Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016 May;39(5):833-46. doi: 10.2337/dc15-2251.
